Viewing Study NCT06534892



Ignite Creation Date: 2024-10-26 @ 3:36 PM
Last Modification Date: 2024-10-26 @ 3:36 PM
Study NCT ID: NCT06534892
Status: RECRUITING
Last Update Posted: None
First Post: 2024-07-30

Brief Title: An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OAADJ-006 Study
Sponsor: None
Organization: None

Study Overview

Official Title: A Phase 3b Randomized Open Label Multicountry Multi-center Extension and Crossover Vaccination Study to Evaluate the Immunogenicity and Safety of Different Revaccination Schedules and Persistence of a Single Dose of the RSVPreF3 OA Vaccine in Adults Aged 60 Years and Above Who Participated in the RSV OAADJ-006 Study
Status: RECRUITING
Status Verified Date: 2024-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: RSV OAADJ012
Brief Summary: The purpose of this study is

To investigate the optimal timing for revaccination after the initial RSVPreF3 OA vaccine dose
To evaluate the long-term immune persistence and safety up to 5 consecutive RSV seasons approximately 60 months of a single dose of RSVPreF3 OA vaccine
To give the opportunity to participants who received only placebo in the RSVOAADJ- 006 study to receive a dose of the RSVPreF3 OA vaccine and collect additional safety information
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None